The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) reached all time low today, Oct, 28 and still has $4.45 target or 14.00% below today’s $5.17 share price. This indicates more downside for the $123.19M company. This technical setup was reported by Barchart.com. If the $4.45 PT is reached, the company will be worth $17.25M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 109,195 shares traded hands or 30.04% up from the average. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 27.70% since March 28, 2016 and is downtrending. It has underperformed by 32.42% the S&P500.
Analysts await Dimension Therapeutics Inc (NASDAQ:DMTX) to report earnings on December, 2. They expect $-0.50 earnings per share, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual earnings per share reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.
Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage
Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Buy” rating by Goldman Sachs on Monday, November 16. On Thursday, February 18 the stock rating was initiated by Cantor Fitzgerald with “Buy”. On Monday, November 16 the stock rating was initiated by Citigroup with “Buy”. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) has “Buy” rating given on Monday, November 16 by Canaccord Genuity. The stock has “Buy” rating given by Roth Capital on Friday, November 6. Goldman Sachs initiated it with “Buy” rating and $20 target price in Friday, December 4 report. Cantor Fitzgerald initiated it with “Buy” rating and $32 target price in Friday, June 3 report.
According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”
More important recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Wsj.com which released: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” on October 22, 2015, also Marketwatch.com published article titled: “Dimension Therapeutics Inc.”, Businesswire.com published: “Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing” on April 21, 2015. More interesting news about Dimension Therapeutics Inc (NASDAQ:DMTX) was released by: Globenewswire.com and their article: “Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered …” with publication date: May 07, 2016.
DMTX Company Profile
Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.